Geron (NASDAQ:GERN) Shares Gap Down – Here’s Why

Geron Corporation (NASDAQ:GERN) gapped down before the market opened on Wednesday . The stock had previously closed at $1.95, but opened at $1.68. Geron shares last traded at $1.7450, with a volume of 9,700,122 shares traded.

Trending Headlines about Geron

Here are the key news stories impacting Geron this week:

• Positive Sentiment: RyTELO commercial momentum — Geron reported RYTELO net product revenue of $48.0M in Q4 and $183.6M for full‑year 2025, with RYTELO demand up 9% sequentially and ~150 new ordering accounts added in Q4, supporting continued top‑line growth. Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
• Positive Sentiment: 2026 revenue guidance reiterated — Management reiterated 2026 RYTELO net product revenue guidance of $220M–$240M, indicating confidence in commercial outlook and providing a measurable growth target for investors. Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
• Neutral Sentiment: Cash runway and cost discipline — Geron ended 2025 with about $401M in cash and marketable securities and reported 2025 operating expense of ~$255M (within prior guidance); management says current resources plus anticipated U.S. RYTELO sales should fund foreseeable needs, but the cash decline from 2024 is notable. Geron Corporation Reports $184 Million in RYTELO® Revenue for 2025 and Provides 2026 Financial Guidance
• Neutral Sentiment: Upcoming catalysts — Management flagged mid‑2026 milestones (IMpactMF interim analysis, initial real‑world trials in LR‑MDS) and scheduled investor presentations (TD Cowen, Barclays) that could move sentiment if results/data surprise. Geron Plans to Present at Upcoming Investor Conferences
• Negative Sentiment: Quarterly loss and perceived miss — The company reported a Q4 net loss of $31.1M and EPS roughly in line with consensus (‑$0.03), but some investors/analysts viewed the results and accompanying metrics as a miss versus expectations, contributing to selling pressure. Geron falls as Q4 results miss expectations
• Negative Sentiment: Restructuring and expense execution — Geron recorded $17M of restructuring charges after cutting ~1/3 of its workforce; SG&A rose as the company invested in sales/marketing. Combined with the cash decline from ~$503M to ~$401M, investors are focused on near‑term cash burn and execution risks. Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
• Negative Sentiment: Analyst reactions and valuation pressure — Some analyst coverage has been cautious (e.g., TD Cowen trimmed its price target earlier), and recent commentary about valuation vs. volatility has kept trading active and pressure on the shares. Geron (GERN) Sets 2026 Financial Goals, TD Cowen Cuts PT

Analyst Ratings Changes

A number of equities analysts have recently issued reports on GERN shares. UBS Group reiterated a “neutral” rating on shares of Geron in a research report on Tuesday, December 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Geron in a research report on Wednesday, January 28th. TD Cowen reissued a “buy” rating on shares of Geron in a research note on Thursday, January 29th. Needham & Company LLC cut their price target on Geron from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Geron in a report on Tuesday, December 9th. Four equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $2.75.

Geron Stock Performance

The company has a current ratio of 5.96, a quick ratio of 4.87 and a debt-to-equity ratio of 0.48. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -13.79 and a beta of 0.62. The stock has a 50 day moving average price of $1.46 and a two-hundred day moving average price of $1.35.

Geron (NASDAQ:GERN) last released its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.03) EPS for the quarter, meeting analysts’ consensus estimates of ($0.03). Geron had a negative return on equity of 29.63% and a negative net margin of 43.61%. Analysts predict that Geron Corporation will post -0.25 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Geron by 2.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company’s stock valued at $627,000 after purchasing an additional 8,123 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Geron by 8.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,372,016 shares of the biopharmaceutical company’s stock worth $2,182,000 after buying an additional 104,840 shares during the period. Vanguard Personalized Indexing Management LLC lifted its holdings in Geron by 204.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 34,238 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 22,993 shares in the last quarter. Savant Capital LLC grew its stake in Geron by 73.8% in the second quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 11,074 shares during the period. Finally, Nan Fung Trinity HK Ltd. bought a new stake in shares of Geron in the second quarter worth about $1,937,000. Institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.